Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.

Citation

• Choueiri, T. K., Figueroa, D. J., Liu, Y., Gagnon, R. C., Deen, K. C., Carpenter, C., . . . Motzer, R. J. (2014). Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.. Journal of Clinical Oncology, 32(4_suppl), 416. doi:10.1200/jco.2014.32.4_suppl.416

Digital Object Identifier (doi)

• 10.1200/jco.2014.32.4_suppl.416

Web Of Science Accession Number

Start Page

• 416

End Page

• 416

Volume

• 32

Issue

• 4_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2014

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Choueiri, T. K., Figueroa, D. J., Liu, Y., Gagnon, R. C., Deen, K. C., Carpenter, C., . . . Motzer, R. J. (2014). Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis.. Journal of Clinical Oncology, 32(4_suppl), 416. doi:10.1200/jco.2014.32.4_suppl.416

Digital Object Identifier (doi)

• 10.1200/jco.2014.32.4_suppl.416

Web Of Science Accession Number

Start Page

• 416

End Page

• 416

Volume

• 32

Issue

• 4_suppl

Place Of Publication